Halozyme proposes $1.05 billion convertible notes due 2033
Halozyme said it intends to offer $1.05 billion of convertible senior notes due 2033, subject to market conditions and other factors. The proposed financing adds potential dilution and interest obligations, while the use of proceeds and final conversion terms will determine the setup for HALO.
PR NEWSWIRE / FILEThe story
Halozyme announced on Sept. 16 that it intends to offer $1.05 billion in aggregate principal amount of convertible senior notes due 2033.
The financing follows a 2025 fiscal year in which Halozyme reported revenue of $1.4 billion, up 37.6% year over year, with diluted EPS of $2.56.
For Halozyme, the direct mechanism is the note structure: debt creates an obligation due in 2033, while the convertible feature can result in equity dilution if holders convert. The company’s revenue growth provides operating context, but does not by itself resolve the cost of the financing or the eventual share impact.
Those terms, along with demand and the final amount issued, remain the material unresolved elements of the transaction.
The next evidence will be the final offering terms and any related filing or closing announcement. The key figures to watch are the coupon, conversion premium, principal amount completed and any stated use of proceeds; no dated event beyond the proposed offering was identified in the announcement.
Our read · Wed, Sep 16
The proposed $1.05 billion convertible financing leaves HALO with a mixed setup: funding flexibility against future dilution and debt-service risk.
Why. The trade read is mixed because the financing can support Halozyme’s next capital allocation while also creating a future dilution channel and a 2033 debt obligation. The company’s 2025 revenue of $1.4 billion, up 37.6% year over year, gives the transaction an operating-growth backdrop, but the missing coupon, conversion price and use of proceeds prevent a clean directional call.
Both cases
What could change this view: The setup changes materially if the final coupon, conversion premium, offering size or use of proceeds differs from the proposed terms.
Who reported it · 1
Keep reading
Latest on the Wire
AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →Latest on the Wire
Trump Media buys back $100 million of notes ahead of Nov. 30 cash demandTrump, Xi and Putin pledge more refined fuel after first trilateral summitSky reserve linked to $518 million in illicit activity, investigation findsBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%Continue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by PR Newswire as Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →